A daily pill can prevent HIV infection, but few take it

Although a daily pill can prevent HIV infection, very few people actually take it.

About 1.2 million Americans are at high risk for HIV and could benefit from taking the pill, sold under the brand name Truvada, in a strategy that doctors call “pre-exposure prophylaxis,” or PrEP, according to a new report from the Centers for Disease Control and Prevention.

Studies in men who have sex with men show that taking PrEP reduces the risk of contracting HIV by 92%. Studies in injection drug users have found that PrEP reduced the risk of infection by more than 70%.

Yet only about 21,000 people – less than 1% of those who could benefit – are taking PrEP, the CDC’s Jonathan Mermin said.

Although the Food and Drug Administration approved Truvada in 2012, one-third of primary care doctors have never heard of PrEP, according to a national survey that has not yet been published.

“We have this sea change in HIV prevention, but it is one of the best-kept secrets in medicine,” said J.D. Davids, managing editor at TheBody.com, an online resource on HIV and AIDS.

Actor Charlie Sheen’s recent HIV disclosure could help spread the word.

In an interview on The Dr. Oz Show last week, Sheen’s former girlfriend, Amanda Bruce, said she took medication to prevent becoming infected with HIV.

Sheen has said that medication reduced his HIV levels to an undetectable level. Although he disclosed that he has not always used condoms, he said that his sexual partners knew about his diagnosis and were under the care of his doctor.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below